US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Inhibitor Therapeutics Inc.

0.0798

0.0000

Volume:- -

Turnover:- -

Market Cap:13.77M

PE:- -

High:0.0798

Open:0.0798

Low:0.0798

Close:0.0798

52wk High:0.0899

52wk Low:0.0338

Shares:172.57M

Float Shares:36.38M

Volume Ratio:2.81

T/O Rate:- -

Dividend:- -

Dividend Rate:- -

ROE:-200.97%

ROA:-46.89%

PB:3988.23

PE(LYR):- -

Loading ...

Overview Company News Filings

Company Profile

Company Name:

Inhibitor Therapeutics Inc.

Exchange:

OTCQB

Establishment Date:

1992

Employees:

6

Office Location:

3014 West Palmira Avenue,Suite 302,Tampa,Florida,United States

Website:

http://www.hedgepathpharma.com

Zip Code:

33629-7264

Phone:

Fax:

- -

Introduction:

Inhibitor Therapeutics, Inc., a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. The company engages in the development of therapies for prostate and lung cancer utilizing SUBA-Itraconazole, an oral formulation of the drug itraconazole; and conducted a positive Phase 2b study of SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome. The company was formerly known as HedgePath Pharmaceuticals, Inc. and changed its name to Inhibitor Therapeutics, Inc. in August 2019. Inhibitor Therapeutics, Inc. was founded in 1992 and is based in Tampa, Florida.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/INTI/company"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"INTI","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"INTI\",,,,,undefined,":{"symbol":"INTI","market":"US","secType":"STK","nameCN":"Inhibitor Therapeutics Inc.","latestPrice":0.0798,"timestamp":1771621200000,"preClose":0.0798,"halted":0,"volume":0,"delay":15,"changeRate":0,"floatShares":36378595,"shares":172573545,"eps":0,"marketStatus":"Pre-Mkt","change":0,"latestTime":"02-20 16:00:00 EST Delay","open":0.0798,"high":0.0798,"low":0.0798,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1771857000000},"marketStatusCode":1,"adr":0,"exchange":"OTCQB","adjPreClose":0.0798,"volumeRatio":2.8056183700890696},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"INTI\",,,,,undefined,":{"symbol":"INTI","floatShares":36378595,"roa":"-46.89%","roe":"-200.97%","lyrEps":0,"volumeRatio":2.8056183700890696,"shares":172573545,"dividePrice":0,"high":0.0798,"amplitude":0,"preClose":0.0798,"low":0.0798,"week52Low":0.0338,"pbRate":"3988.23","week52High":0.0899,"institutionHeld":0,"latestPrice":0.0798,"eps":0,"divideRate":0,"volume":0,"delay":15,"open":0.0798,"prevYearClose":0.045,"prevWeekClose":0.0798,"prevMonthClose":0.0778,"prevQuarterClose":0.045,"fiveDayClose":0.067,"twentyDayClose":0.08,"sixtyDayClose":0.0495},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/INTI\",params:#limit:5,,,undefined,":[{"market":"US","date":"2024-11-12","symbol":"INTI","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1731387600000,"reportTimeType":"pre","actualEps":null},{"market":"US","date":"2024-08-06","symbol":"INTI","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1722916800000,"reportTimeType":"pre","actualEps":null},{"market":"US","date":"2024-05-13","symbol":"INTI","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1715572800000,"reportTimeType":"pre","actualEps":null},{"market":"US","date":"2024-03-29","symbol":"INTI","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1711684800000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2023-11-13","symbol":"INTI","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1699851600000,"reportTimeType":"pre","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"INTI\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"INTI\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{"companyId":369680,"yearFounded":1992,"employeeNum":6,"address":"3014 West Palmira Avenue,Suite 302,Tampa,Florida,United States","zipCode":"33629-7264","officePhone":"813 864 2562"},"stockCompanyDetail":{"websiteUrl":"http://www.hedgepathpharma.com","stockEarnings":[{"period":"1week","weight":0.2201},{"period":"1month","weight":0.1283},{"period":"3month","weight":-0.1548},{"period":"ytd","weight":-0.1548}],"description":"Inhibitor Therapeutics, Inc., a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. The company engages in the development of therapies for prostate and lung cancer utilizing SUBA-Itraconazole, an oral formulation of the drug itraconazole; and conducted a positive Phase 2b study of SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome. The company was formerly known as HedgePath Pharmaceuticals, Inc. and changed its name to Inhibitor Therapeutics, Inc. in August 2019. Inhibitor Therapeutics, Inc. was founded in 1992 and is based in Tampa, Florida.","exchange":"OTCQB","name":"Inhibitor Therapeutics Inc.","nameEN":"Inhibitor Therapeutics Inc."}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"INTI\",market:\"US\",,,undefined,":null}}